Abstract
The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG 1.36, 95 % CI 1.11–1.67 and rs11856927, ORGG 1.35, 95 % CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (p adj = 0.03); risk was increased in postmenopausal (ORAA 1.22, 95 % CI 1.05–1.14), but not premenopausal (ORAA 0.78, 95 % CI 0.64–0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.
Similar content being viewed by others
References
Simpson ER et al (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15(3):342–355
Mahendroo MS et al (1991) Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. J Biol Chem 266(17):11276–11281
Hulka BS, Liu ET, Lininger RA (1994) Steroid hormones and risk of breast cancer. Cancer 74(3 Suppl):1111–1124
Eliassen AH et al (2012) Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 72(3):696–706
Key T et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616
Henderson BE, Ponder B, Ross R (2003) Hormones, genes, and cancer. Oxford University Press, New York 450
Bulun SE et al (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77(6):1622–1628
Platet N et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55–67
Saha Roy S, Vadlamudi RK (2012) Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012:654698
Dunning AM et al (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96(12):936–945
Beckmann L et al (2011) Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab 96(2):E360–E367
Lundin E et al (2012) Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer. Cancer Epidemiol 36(5):445–452
Haiman CA et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893–1897
Riancho JA et al (2007) Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 92(2):660–665
Clendenen T et al (2013) Genetic variants in hormone-related genes and risk of breast cancer. PLoS ONE 8(7):e69367
Zhang B et al (2011) Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 12(5):477–488
Canzian F et al (2010) Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet 19(19):3873–3884
Chen C et al (2008) Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai China. Cancer Epidemiol Biomarkers Prev 17(12):3457–3466
Kristensen VN et al (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19(10):1329–1333
Olson JE et al (2007) A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 102(2):237–247
Fasching PA et al (2008) Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 112(1):89–98
Long JR et al (2006) Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 15(11):2115–2122
Udler MS et al (2009) Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 125(11):2687–2696
Goode EL et al (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62(11):3052–3057
Huang CS et al (2008) The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I–II and operable stage III breast cancers. Oncologist 13(7):751–760
Kuo SH et al (2013) CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer. Biomed Res Int 2013:562197
Price AL et al (2007) A genomewide admixture map for Latino populations. Am J Hum Genet 80(6):1024–1036
Slattery M et al (2012) Genetic variation in genes involved in hormones, inflammation, and energetic factors and breast cancer risk in an admixed population. Carcinogenesis 33(8):1512–1521
Fejerman L et al (2010) European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol Biomarkers Prev 19(4):1074–1082
Fejerman L et al (2012) Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas. Hum Mol Genet 21(8):1907–1917
Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163:49–56
Hines LM et al (2010) Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer 116(13):3215–3223
Hines LM et al (2011) Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. J Womens Health (Larchmt) 20(10):1543–1550
Boone SD et al (2014) The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women. Cancer Causes Control 25(3):273–282
Li R et al (2002) Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women. Cancer 95(5):960–968
Gonzalez Burchard E (2005) Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am J Public Health 95(12):2161–2168
Slattery ML et al (2007) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat 102(1):85–101
John EM, Horn-Ross PL, Koo J (2003) Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev 12(11 Pt 1):1143–1152
John EM et al (2005) Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol Biomarkers Prev 14(12):2905–2913
Angeles-Llerenas A et al (2010) Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control 21(4):577–586
Carlson CS et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74(1):106–120
Stram DO et al (2003) Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the multiethnic cohort study. Hum Hered 55(1):27–36
Collins-Schramm HE et al (2004) Mexican American ancestry-informative markers: examination of population structure and marker characteristics in European Americans, Mexican Americans Amerindians and Asians. Hum Genet 114(3):263–271
WHO (1992) International statistical classification of diseases and related health problems (10th revision). World Health Organization, Geneva
Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155(2):945–959
Dubin N, Pasternack BS (1986) Risk assessment for case–control subgroups by polychotomous logistic regression. Am J Epidemiol 123(6):1101–1117
Hosmer D Jr, Lemeshow S (1989) Applied logistic regression. Probability and mathematical statistics. Wiley, New York
Bursac Z et al (2008) Purposeful selection of variables in logistic regression. Source Code Biol Med 3:17
Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70
Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74(4):765–769
Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 95(3):221–227
Yue W et al (1998) In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58(5):927–932
Talbott KE et al (2008) A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 111(3):481–487
Zins K et al (2014) Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer. Int J Mol Sci 15(1):712–724
Haiman CA et al (2002) No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 11(2):215–216
Haiman CA et al (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87(2):204–210
Haiman CA et al (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the multiethnic cohort. Hum Mol Genet 12(20):2679–2692
Reding KW et al (2012) Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control 23(5):671–681
Yoshimoto N et al (2011) Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci 102(11):2065–2072
Diergaarde B et al (2008) Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 17(7):1751–1759
Johnson AD et al (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24(24):2938–2939
International HapMap C (2003) The International HapMap Project. Nature 426(6968):789–796
Pineda B et al (2013) Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case–control to a meta-analysis of 20,098 subjects. PLoS One 8(1):e53902
Zhang L et al (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114(2):327–338
Miron L et al (2012) Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer. Rev Med Chir Soc Med Nat Iasi 116(4):997–1004
Acknowledgments
We would also like to acknowledge the contributions of the following individuals to the study: Sandra Edwards for data harmonization oversight; Erica Wolff and Michael Hoffman for laboratory support; Carolina Ortega for her assistance with data management for the Mexico Breast Cancer Study, Jocelyn Koo for data management for the San Francisco Bay Area Breast Cancer Study, Dr. Tim Byers for his contribution to the 4-Corner’s Breast Cancer Study, and Dr. Josh Galanter for assistance in selection of AIMs markers. The Breast Cancer Health Disparities Study was funded by Grant CA14002 from the National Cancer Institute to Dr. Slattery. The San Francisco Bay Area Breast Cancer Study was supported by Grants CA63446 and CA77305 from the National Cancer Institute, Grant DAMD17-96-1-6071 from the U.S. Department of Defense and Grant 7PB-0068 from the California Breast Cancer Research Program. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract HHSN261201000036C awarded to the Cancer Prevention Institute of California; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The 4-Corners Breast Cancer Study was funded by Grants CA078682, CA078762, CA078552, and CA078802 from the National Cancer Institute. The research also was supported by the Utah Cancer Registry, which is funded by contract N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the New Mexico Tumor Registry, and the Arizona and Colorado cancer registries, funded by the Centers for Disease Control and Prevention National Program of Cancer Registries and additional state support. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute or endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. The Mexico Breast Cancer Study was funded by Consejo Nacional de Ciencia y Tecnología (CONACyT) (SALUD-2002-C01-7462).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Boone, S.D., Baumgartner, K.B., Baumgartner, R.N. et al. Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study. Cancer Causes Control 25, 1461–1471 (2014). https://doi.org/10.1007/s10552-014-0448-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-014-0448-5